secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rain Oncology Inc. (—)
CIK:        0001724979
Form:       8-K
Filed at:   2024-01-26T23:59:59+00:00
Accession:  0001999371-24-000886
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rain Oncology acquired by Pathos AI for $1.16/share + CVR; stock to be delisted
-------------------------------------------------------------------------------

- Tender offer closed with 77% of shares tendered; all shares purchased for $1.16 cash plus one contingent value right (CVR) per share.
- At merger close, board of directors resigned; new directors and officers from Pathos AI include CEO Ryan Fukushima and CFO Zack Malkin.
- CVRs provide potential payments: $1M milestone on first patient dosing of milademetan, or 80% of net proceeds from disposition; also cash payments from excess cash or litigation settlement.
- Company requested Nasdaq delisting and SEC deregistration; will file Form 15 to suspend reporting obligations.
- Merger completed under DGCL Section 251(h) without stockholder vote; Rain becomes wholly owned subsidiary of Pathos AI.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1724979/000199937124000886/0001999371-24-000886-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1724979/000199937124000886/rain-8k_012624.htm
  HTML page:      https://secwatch.observer/filing/0001999371-24-000886

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer